CA-NETAPP,-INC.
20.10.2021 17:02:11 CEST | Business Wire | Press release
NetApp (NASDAQ: NTAP) a global, cloud-led, data-centric software company, today announced continued growth and momentum helping organizations unlock the best of cloud at less cost, through its collaboration with the world’s three largest public clouds.
NetApp’s expansion in the cloud has been driven by customers and supported by these partnerships, accelerating NetApp’s public cloud services’ customer and financial growth by bringing its leading CloudOps and ITOps solutions to existing and new addressable customers. Furthering its investment in the cloud, NetApp acquired Data Mechanics in early fiscal year (FY)’22, and this month announced the intent to acquire CloudCheckr to bolster the Spot by NetApp portfolio’s existing continuous cloud optimization capabilities.
This growth, driven by NetApp’s ONTAP data management software, which provides high-performance shared storage for file and block workloads, has propelled the native integration of NetApp’s cloud file services into each of the major public clouds.
“The three largest public clouds in the world are choosing NetApp, because customers are choosing ONTAP,” said Anthony Lye, Executive Vice President & General Manager, Public Cloud Services at NetApp. “Our strategy has positioned ONTAP as the native shared storage solution with rich data services inside the three public clouds. Now, our public cloud partners provide customers with the simplest path to the cloud and allow them to derive the most value from their data and applications.”
“The completeness of NetApp’s offering, combined with the ability to address a very broad set of storage use cases beyond cloud file storage, and the availability as a Tier 1 offering both on AWS and Azure, makes it a compelling choice,” said Enrico Signoretti, Senior Data Storage Analyst at GigaOm.1
Microsoft Azure
NetApp has partnered with Microsoft for nearly 30 years. In 2021 Microsoft recognized NetApp as the global Customer Experience Partner of the Year , and the U.S. SAP on Azure Partner of the Year . In the last 12 months, NetApp has more than tripled the number of co-sells offered on the Azure Marketplace, making it easy for Azure customers to consume NetApp’s leading cloud services.
Since its general availability in 2019, Azure NetApp Files (ANF), a fully managed, first-party service sold, billed, and supported by Microsoft in 35+ regions globally and is the first and only shared file service certified for use with SAP HANA. Recent innovations with Azure include the general availability of Azure Cross Region Replication, public preview of Azure NetApp Files Backup to preserve storage efficiencies, and of Spot PC for secure, optimized Azure Virtual Desktop-based Cloud PC environments.
“Alongside NetApp, we have worked with ANF customers to successfully migrate and run some of their largest and most important ONTAP production workloads, enabling the most demanding applications with performance and scale that meets or beats what they get on-premises,” said Jurgen Willis, Vice President, Product Management at Microsoft Azure Storage.
“With ANF, we get scalability and flexibility, which is important for businesses to run and have a faster time-to-market for their products,” said Lalit Patel, Chief Technology Officer, Enterprise Cloud Services at SAP. “We are able to deploy environments almost 30 to 40 percent faster and reduce the number of outages by 80 percent because of the stability that ANF provides.”
Google Cloud
NetApp and Google Cloud began collaborating in 2018, introduced NetApp Cloud Volumes Service (CVS) for Google Cloud in 2019, and launched NetApp Astra with support for Google Cloud in 2020. Earlier this month Google announced that NetApp would serve as the primary data and storage vendor for its new Google Distributed Cloud Hosted offering and introduced the integration of Google Cloud VMware Engine with NetApp Cloud Volumes Service support for VM datastores - a fully managed service that helps organizations meet their need for virtual workload storage and disaster recovery.
“Our partnership with NetApp continues to grow, rolling out new capabilities that will make it easier and more cost-effective to deliver enterprise workloads on Google Cloud and bringing customers even more flexibility across hybrid and cloud deployments,” said Bronwyn Hastings, Vice President Global Technology Partnerships at Google Cloud.
“With NetApp's deep integrations with Google Cloud, we're reaping all of the benefits of the cloud as a service, with configurations preset, elasticity built-in and disaster recovery capabilities in place within five minutes,” said Tom Gentry, Technologist at Gunpowder. “By making the technology challenges disappear for these studios, we're able to deliver the high performance our customers need anywhere in the world.”
Additionally, Spot by NetApp and Google Cloud have partnered to help companies take full advantage of the recently announced Google Spot VMs . With this, Google Cloud customers can continuously optimize performance, availability and cost with Spot by NetApp for cloud cost savings without the risk of service interruption.
Additional Resources
- Press Release: NetApp Expands Hybrid Cloud Solutions Portfolio to Unlock Best of Cloud at INSIGHT 2021 Digital
- Blog post: Ungated Innovation: Azure NetApp Files
- Blog post: NetApp INSIGHT ‘21 - Google Cloud Momentum
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
1 Source: GigaOm, Radar for Cloud File Systems, September 22, 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005583/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom